There are 2949 resources available
576P - The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic model
Presenter: Guen Tae Kim
Session: E-Poster Display
Resources:
Abstract
577P - Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours
Presenter: Binghe Xu
Session: E-Poster Display
Resources:
Abstract
578P - Interim analysis of a phase II study of SHR-1210 combined with neoadjuvant chemoradiation in patients with locally advanced proximal stomach adenocarcinoma (Neo-PLANET)
Presenter: Xuefei Wang
Session: E-Poster Display
Resources:
Abstract
579P - MORAb-109: A site-specific eribulin-conjugated ADC targeting human mesothelin
Presenter: Earl Albone
Session: E-Poster Display
Resources:
Abstract
580P - AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection
Presenter: Remko Schotte
Session: E-Poster Display
Resources:
Abstract
581P - VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumour immune microenvironment
Presenter: Francesco Mancuso
Session: E-Poster Display
Resources:
Abstract
582P - Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL
Presenter: Julien Villaudy
Session: E-Poster Display
Resources:
Abstract
583P - Effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (E7389-LF): Results from the expansion part of a phase I study
Presenter: Satoru Iwasa
Session: E-Poster Display
Resources:
Abstract
584P - Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
Presenter: Paul Paik
Session: E-Poster Display
Resources:
Abstract
585P - Trends in patient-reported outcome (PRO) use in early phase oncology trials
Presenter: Julia Lai-Kwon
Session: E-Poster Display
Resources:
Abstract